



## Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022

May 9, 2022

SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its *Human-First Discovery*<sup>®</sup> platform to develop a novel class of orally administered biological drugs, today announced it will host a conference call and live webcast on Monday, May 16, 2022 at 8:00am ET to discuss updates to its development programs and other business highlights.

The conference call can be accessed by dialing (833) 649-1186 (domestic) or (270) 823-1080 (international) and entering conference ID 8451806. The live webcast can be accessed by visiting the 'Investors & News' section of the Finch Therapeutics website and selecting '[Events & Presentations](#)'. The webcast will be archived on the Finch website for approximately 30 days following the event.

### About Finch Therapeutics

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its *Human-First Discovery*<sup>®</sup> platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch's lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent *C. difficile* infection and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. Finch is also developing FIN-211 for children with autism spectrum disorder and significant gastrointestinal symptoms. Finch has a partnership with Takeda focused on the development of targeted microbiome therapeutics for inflammatory bowel disease. Finch routinely posts information that may be important to its investors on its website at [www.finchtherapeutics.com](http://www.finchtherapeutics.com). Finch encourages investors to consult the "Investors & News" section of its website regularly.

*Human-First Discovery*<sup>®</sup> is a registered trademark of Finch Therapeutics Group, Inc.

### Investor Contact:

Stephen Jasper  
Gilmartin Group  
(858) 525-2047  
[stephen@gilmartinir.com](mailto:stephen@gilmartinir.com)

### Media Contact:

Jenna Urban  
Berry & Company Public Relations  
(212) 253-8881  
[jurban@berrypr.com](mailto:jurban@berrypr.com)